Value through Innovation11 February 2016

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive


IPF Phase III results published in NEJM show nintedanib* slows disease progression

- For non-US health media only

As the benefits and safety of Pradaxa® (dabigatran etexilate) are once again confirmed, Boehringer Ingelheim continues to look for new ways for Pradaxa® to help more patients

- For media outside of the U.S., the UK & Canada only

New analysis shows Boehringer Ingelheim’s Giotrif® (afatinib) is the first treatment to demonstrate significant overall survival benefit for patients with a specific type of lung cancer

- For Ex-US and Ex-UK Media Only

Boehringer Ingelheim will make detailed clinical trial data available to the scientific community


New study to investigate dabigatran etexilate for prevention of recurrent stroke in high-risk patients

- For media outside of the U.S., the UK & Canada only

New registry data highlight substantial global differences in stroke prevention for patients with an irregular heart beat

- For media outside of the U.S., the UK & Canada only

Type 2 Diabetes Research: Connexios Life Sciences and Boehringer Ingelheim Enter Agreement for Novel AMPK Activators


Boehringer Ingelheim Animal Health announces the 2014 European PRRS Research Award


Boehringer Ingelheim to present highly anticipated Phase III data in IPF and COPD at ATS International Conference

- For media outside UK, U.S. and Canada

Positive CHMP opinion for Pradaxa® in treatment of deep vein thrombosis and pulmonary embolism and prevention of repeat blood clots

- For media outside of the U.S., the UK & Canada only

Hydra Biosciences and Boehringer Ingelheim announce worldwide collaboration to develop small-molecule inhibitors for the treatment of central nervous system diseases and disorders


Volasertib, Boehringer Ingelheim´s investigational treatment of acute myeloid leukaemia, is granted ‘orphan drug designation’ in the EU and the US

- For media outside of the US only

Boehringer Ingelheim receives “Facility of the Year Award” for Equipment Innovation in biopharmaceutical manufacturing


Boehringer Ingelheim pleased with 2013 financial year


Boehringer Ingelheim Animal Health supports PCV2 research projects with 500,000 euro


FDA approves Pradaxa® for treatment and reduction in risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE)

- For media outside of the U.S., the UK & Canada only

New Pradaxa® data to be presented during the American College of Cardiology’s 63rd Annual Scientific Session

- For media outside of the US, the UK & Canada only

Type 2 Diabetes: CHMP recommends empagliflozin* for approval

- For Non-US and Non-UK Media